美国医院金黄色葡萄球菌分离株的抗菌药物敏感性趋势：2010 年至 2016 年头孢洛林（AWARE）监测计划的 7 年结果。
Antimicrobial Susceptibility Trends among Staphylococcus aureus Isolates from U.S. Hospitals: Results from 7 Years of the Ceftaroline (AWARE) Surveillance Program, 2010 to 2016.
机构信息
JMI Laboratories, North Liberty, Iowa, USA
JMI Laboratories, North Liberty, Iowa, USA.
出版信息
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.01043-17. Print 2017 Sep.
Abstract
We evaluated trends in antimicrobial susceptibility in U.S. hospitals in the 2010-2016 period. A total of 21,056 clinical isolates from 42 medical centers were tested for susceptibility by broth microdilution methods. Methicillin-resistant (MRSA) rates decreased from 50.0% (in 2010) to 42.2% (in 2016). Susceptibility to erythromycin, levofloxacin, and clindamycin increased slightly, whereas susceptibility to ceftaroline, trimethoprim-sulfamethoxazole, and tetracycline remained stable. Ceftaroline retained potent activity against methicillin-susceptible (MSSA) and MRSA (97.2% susceptible) with no marked variations.
摘要
我们评估了 2010-2016 年期间美国医院中抗菌药物敏感性的趋势。对来自 42 个医疗中心的 21056 株临床分离株进行肉汤微量稀释法药敏试验。耐甲氧西林金黄色葡萄球菌（MRSA）的发生率从 50.0%（2010 年）下降至 42.2%（2016 年）。对红霉素、左氧氟沙星和克林霉素的敏感性略有增加，而对头孢洛林、复方磺胺甲噁唑和四环素的敏感性保持稳定。头孢洛林对甲氧西林敏感金黄色葡萄球菌（MSSA）和 MRSA 保持强效活性（97.2%敏感），无明显变化。
相似文献
1
Antimicrobial Susceptibility Trends among Staphylococcus aureus Isolates from U.S. Hospitals: Results from 7 Years of the Ceftaroline (AWARE) Surveillance Program, 2010 to 2016.
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.01043-17. Print 2017 Sep.
2
Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009.
Antimicrob Agents Chemother. 2011 Sep;55(9):4154-60. doi: 10.1128/AAC.00315-11. Epub 2011 Jun 27.
3
Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program.
Clin Infect Dis. 2012 Sep;55 Suppl 3:S181-6. doi: 10.1093/cid/cis560.
4
Antimicrobial Activity of Ceftaroline Tested against Staphylococcus aureus from Surgical Skin and Skin Structure Infections in US Medical Centers.
Surg Infect (Larchmt). 2016 Aug;17(4):443-7. doi: 10.1089/sur.2015.209. Epub 2016 Mar 18.
5
In vitro antimicrobial activity of ozenoxacin against methicillin-susceptible Staphylococcus aureus, methicillin-resistant S. aureus and Streptococcus pyogenes isolated from clinical cutaneous specimens in Japan.
J Infect Chemother. 2016 Oct;22(10):720-3. doi: 10.1016/j.jiac.2016.03.006. Epub 2016 Apr 16.
6
Antimicrobial susceptibility patterns of community- and hospital-acquired methicillin-resistant Staphylococcus aureus from United States Hospitals: results from the AWARE Ceftaroline Surveillance Program (2012-2014).
Diagn Microbiol Infect Dis. 2016 Sep;86(1):76-9. doi: 10.1016/j.diagmicrobio.2016.06.017. Epub 2016 Jun 23.
7
Impact of EUCAST ceftaroline breakpoint change on the susceptibility of methicillin-resistant Staphylococcus aureus isolates collected from patients with complicated skin and soft-tissue infections.
Clin Microbiol Infect. 2019 Nov;25(11):1429.e1-1429.e4. doi: 10.1016/j.cmi.2019.03.023. Epub 2019 Apr 10.
8
Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009-13).
J Antimicrob Chemother. 2015 Jul;70(7):2053-6. doi: 10.1093/jac/dkv076. Epub 2015 Mar 25.
9
In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolated in 2012 from Asia-Pacific Countries as Part of the AWARE Surveillance Program.
Antimicrob Agents Chemother. 2015 Oct 26;60(1):343-7. doi: 10.1128/AAC.01867-15. Print 2016 Jan.
10
A multicentre study of meticillin-resistant Staphylococcus aureus in acute bacterial skin and skin-structure infections in China: susceptibility to ceftaroline and molecular epidemiology.
Int J Antimicrob Agents. 2015 Apr;45(4):347-50. doi: 10.1016/j.ijantimicag.2014.12.014. Epub 2015 Jan 15.
引用本文的文献
1
Clinical presentation, treatment, and antimicrobial susceptibility of 155 sequential infections.
Microbiol Spectr. 2025 Apr;13(4):e0274924. doi: 10.1128/spectrum.02749-24. Epub 2025 Mar 10.
2
Ceftobiprole activity against multidrug-resistant clinical isolates collected in the United States from 2016 through 2022.
Antimicrob Agents Chemother. 2025 Feb 13;69(2):e0140224. doi: 10.1128/aac.01402-24. Epub 2025 Jan 13.
3
Ceftaroline Fosamil for the Treatment of Methicillin-Resistant Staphylococcus Aureus Bacteremia: A Real-World Comparative Clinical Outcomes Study.
Drugs Real World Outcomes. 2024 Jun;11(2):273-283. doi: 10.1007/s40801-024-00422-5. Epub 2024 Apr 2.
4
Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant pneumonia.
Eur Respir Rev. 2023 Oct 18;32(170). doi: 10.1183/16000617.0117-2023. Print 2023 Dec 31.
5
Resistance to antibacterial antifolates in multidrug-resistant Staphylococcus aureus: prevalence estimates and genetic basis.
J Antimicrob Chemother. 2023 May 3;78(5):1201-1210. doi: 10.1093/jac/dkad063.
6
Predominance of t355/ST152/SCCmec V clonal type among PVL-positive MRSA isolates in a tertiary care hospital in Belgrade, Serbia.
PLoS One. 2022 Sep 8;17(9):e0273474. doi: 10.1371/journal.pone.0273474. eCollection 2022.
7
The Risk of Emerging Resistance to Trimethoprim/Sulfamethoxazole in .
Infect Drug Resist. 2022 Aug 23;15:4779-4784. doi: 10.2147/IDR.S375588. eCollection 2022.
8
Activity of Oritavancin against Gram-Positive Pathogens Causing Bloodstream Infections in the United States over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010-2019).
Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0166721. doi: 10.1128/AAC.01667-21. Epub 2021 Nov 22.
9
Use of oral tetracyclines in the treatment of adult outpatients with skin and skin structure infections: Focus on doxycycline, minocycline, and omadacycline.
Pharmacotherapy. 2021 Nov;41(11):915-931. doi: 10.1002/phar.2625. Epub 2021 Oct 5.
10
Genomic Update of Phenotypic Prediction Rule for Methicillin-Resistant Staphylococcus aureus (MRSA) USA300 Discloses Jail Transmission Networks with Increased Resistance.
Microbiol Spectr. 2021 Sep 3;9(1):e0037621. doi: 10.1128/Spectrum.00376-21. Epub 2021 Jul 21.
本文引用的文献
1
Life After USA300: The Rise and Fall of a Superbug.
J Infect Dis. 2017 Feb 15;215(suppl_1):S71-S77. doi: 10.1093/infdis/jiw444.
2
Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014.
Infect Control Hosp Epidemiol. 2016 Nov;37(11):1288-1301. doi: 10.1017/ice.2016.174. Epub 2016 Aug 30.
3
Antimicrobial Activity of Ceftaroline Tested against Staphylococcus aureus from Surgical Skin and Skin Structure Infections in US Medical Centers.
Surg Infect (Larchmt). 2016 Aug;17(4):443-7. doi: 10.1089/sur.2015.209. Epub 2016 Mar 18.
4
Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013.
Diagn Microbiol Infect Dis. 2015 May;82(1):78-84. doi: 10.1016/j.diagmicrobio.2015.01.015. Epub 2015 Feb 10.
5
Ceftaroline activity tested against bacterial isolates from pediatric patients: results from the assessing worldwide antimicrobial resistance and evaluation program for the United States (2011-2012).
Pediatr Infect Dis J. 2014 Aug;33(8):837-42. doi: 10.1097/INF.0000000000000307.
6
Staphylococcus aureus bacteremia at 5 US academic medical centers, 2008-2011: significant geographic variation in community-onset infections.
Clin Infect Dis. 2014 Sep 15;59(6):798-807. doi: 10.1093/cid/ciu410. Epub 2014 May 30.
7
Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.
Drugs. 2013 Jul;73(10):1067-94. doi: 10.1007/s40265-013-0075-6.
8
Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011.
Antimicrob Agents Chemother. 2013 Jul;57(7):3178-81. doi: 10.1128/AAC.00484-13. Epub 2013 Apr 29.
9
Community-associated MRSA: what makes them special?
Int J Med Microbiol. 2013 Aug;303(6-7):324-30. doi: 10.1016/j.ijmm.2013.02.007. Epub 2013 Mar 19.
10
Antimicrobial resistance: Not community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)! A clinician's guide to community MRSA - its evolving antimicrobial resistance and implications for therapy.
Clin Infect Dis. 2011 Jan 1;52(1):99-114. doi: 10.1093/cid/ciq067.
Zotero 插件